摘要
目的:观察参附注射液对老年慢性肺心病心力衰竭的疗效、血浆氨基末端B型利钠肽前体(NT-proBNP)以及对血气分析的影响。方法:108例老年慢性肺心病患者随机分成两组,对照组、治疗组各54例,对照组常规吸氧、抗感染、利尿、强心、扩血管等治疗,治疗组在常规治疗同时静脉滴注参附注射液60 ml/天;治疗前后对心力衰竭、NT—proBNP及血气分析评定。结果:对照组显效11例,有效28例,无效12例,恶化3例,总有效率72.2%;治疗组显效14例,有效34例,无效5例,恶化1例,总有效率88.9%,治疗组总有效率高于对照组,差异有统计学意义(P<0.05);治疗组NT—proBNP较对照组改善亦明显(P<0.05);治疗组较对照组血气分析结果得到明显改善:PaO2、SaO2升高,PaCO2降低(P<0.01)。结论:老年慢性肺心病心力衰竭患者在常规综合治疗基础上联合使用参附注射液可提高疗效。
We aimed to assess the clinical efficiency of Shenfu Injection on chronic heart failure of elderly patients(≥ 60years) with pulmonary heart disease.Methods: 108 elderly patients with chronic heart failure of pulmonary heart disease were enrolled.54 patients were randomly allocated to receive Shenfu Injection and routine therapy(Shenfu group) and 54 were allocated to receive only routine treatment(controlled group) such as oxygen,anti-infection,diuretic,cardiotonic,vasodilator and other therapeutic measures.The effect of treatment for chronic heart failure between the two groups was compared.In addition,the precursor of plasma amino-terminal pro-B-type natriuretic peptide(NT-proBNP),blood gas analysis were assessed during the study period.Results: Individuals in the Shenfu group had a greater improvement in heart function than those in controlled group(88.9% vs 77.2%,P<0.05).The serum level of NT-proBNP was significantly lower in the Shenfu group(P<0.05).Furthermore,the blood gas analysis in Shenfu group compared with the controlled group was significantly improved(P<0.01).Conclusion: The combination of Shenfu Injection and routine treatment in elderly patients with chronic heart failure of pulmonary heart disease can improve the therapeutic effect.
出处
《四川中医》
2013年第8期100-101,共2页
Journal of Sichuan of Traditional Chinese Medicine
关键词
参附注射液
治疗
肺心病
心力衰竭
随机对照试验
Shenfu Injection
Treatment
pulmonary heart disease
Chronic heart failure
Elderly patients
Randomized controlled trial
